| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Travere Therapeutics, Inc. | Chief Medical Officer | Common Stock | 47,614 | $426,621 | $8.96 | 17 Aug 2021 | Direct |
| Verrica Pharmaceuticals Inc. | CMO | Common Stock | 2,357 | $9,999 | $4.24 | 25 Nov 2025 | Direct |
| Verrica Pharmaceuticals Inc. | CMO | Employee Stock Option (right to buy) | 325,000 | 24 Mar 2025 | Direct | ||
| Verrica Pharmaceuticals Inc. | CMO | Series C Warrant (right to buy) | 589 | 25 Nov 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc. | 25 Nov 2025 | 2 | +$10,000 | 4 | CMO | 25 Nov 2025, 19:00 |
| VRCA | Verrica Pharmaceuticals Inc. | 24 Mar 2025 | 1 | $0 | 4 | CMO | 26 Mar 2025, 07:10 |
| VRCA | Verrica Pharmaceuticals Inc. | 24 Mar 2025 | 0 | $0 | 3 | CMO | 26 Mar 2025, 07:08 |
| TVTX | Travere Therapeutics, Inc. | 13 Aug 2021 | 2 | -$24,085 | 4 | Chief Medical Officer | 17 Aug 2021, 19:39 |
| TVTX | Travere Therapeutics, Inc. | 28 Jul 2021 | 1 | -$17,262 | 4 | Chief Medical Officer | 29 Jul 2021, 16:09 |
| TVTX | Travere Therapeutics, Inc. | 11 May 2021 | 2 | -$14,475 | 4 | Chief Medical Officer | 13 May 2021, 16:11 |